Parathyroid hormone (1-34) (human)
(Synonyms: 特立帕肽; Human parathyroid hormone-(1-34); hPTH (1-34)) 目录号 : GP10069
Parathyroid hormone (1-34) (human)是人类甲状旁腺激素（PTH）的N端片段（34个氨基酸），是甲状旁腺激素1（PTH1）受体的激动剂。
Cas No.:52232-67-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Parathyroid hormone (1-34) (human) is the N-terminal fragment (34 amino acids) of human Parathyroid hormone (PTH) and is an agonist of the Parathyroid hormone 1 (PTH1) receptor[1]. PTH is essential for the regulation of extracellular Ca2+ and phosphate metabolism[2]. Parathyroid hormone (1-34) (human) can be used to treat osteoporosis. Injection of Parathyroid hormone (1-34) (human) can increase bone formation and bone mass without causing hypercalcemia[3, 4].
In vitro, Parathyroid hormone (1-34) (human) (0, 1, 10, 100nM) treatment of primary human osteoblasts for 24h induced an increase in angiopoietin 1 (Ang-1) mRNA expression. The 10nM dose increased the expression of Ang-1 mRNA by 2-fold (207%±6.4), but increasing the dose to 100nM did not further increase the expression level of Ang-1 mRNA[5].
In vivo, subcutaneous administration of Parathyroid hormone (1-34) (human) (20μg/kg/day) to mature rabbits for 4 weeks increased the cortical bone porosity, number and density, as well as the cortical area, thickness and bone mineral content (BMC) of the distal femoral shaft, but had no significant effect on volumetric bone mineral density (BMD)[6].
References:
[1] Hoare S R J, Usdin T B. Molecular mechanisms of ligand recognition by parathyroid hormone 1 (PTH1) and PTH2 receptors[J]. Current pharmaceutical design, 2001, 7(8): 689-713.
[2] Goltzman D. Physiology of parathyroid hormone[J]. Endocrinology and Metabolism Clinics, 2018, 47(4): 743-758.
[3] Kim E S, Keating G M. Recombinant human parathyroid hormone (1–84): a review in hypoparathyroidism[J]. Drugs, 2015, 75: 1293-1303.
[4] Neer R M, Arnaud C D, Zanchetta J R, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis[J]. New England journal of medicine, 2001, 344(19): 1434-1441.
[5] Park J H, Song H I, Rho J M, et al. Parathyroid hormone (1-34) augments angiopoietin-1 expression in human osteoblast-like cells[J]. Experimental and clinical endocrinology & diabetes, 2006, 114(08): 438-443.
[6] Iwamoto J, Seki A, Nango N. Influence of teriparatide and ibandronate on cortical bone in New Zealand white rabbits: A HR-QCT study[J]. Calcified tissue international, 2016, 99(5): 535-542.
Parathyroid hormone (1-34) (human)是人类甲状旁腺激素（PTH）的N端片段（34个氨基酸），是甲状旁腺激素1（PTH1）受体的激动剂[1]。PTH对于细胞外Ca2+和磷酸盐代谢的调节至关重要[2]。Parathyroid hormone (1-34) (human)可用于治疗骨质疏松症，注射Parathyroid hormone (1-34) (human)可以增加骨形成和骨量，而不会引起高钙血症[3, 4]。
在体外，Parathyroid hormone (1-34) (human)（0, 1, 10, 100nM）处理原代人类成骨细胞24h，诱导了血管生成素1（Ang-1）mRNA表达增加。10nM剂量下使Ang-1 mRNA的表达增加了2倍（207%±6.4），但剂量提高至100nM不会进一步增加Ang-1 mRNA表达水平[5]。
在体内，Parathyroid hormone (1-34) (human)（20μg/kg/day）通过皮下注射治疗成熟家兔4周，增加了股骨远端骨干的皮质骨孔隙比、数量和密度以及皮质面积、厚度和骨矿物质含量（BMC），但对体积骨矿物质密度（BMD）没有显著影响[6]。
| Cell experiment [1]: | |
Cell lines | Primary cultured human osteoblasts |
Preparation Method | Primary cultured human osteoblasts were cultured in the presence of 0, 1, 10, and 100nM Parathyroid hormone (1-34) (human) for 24h. The expression of Ang-1 mRNA was analyzed by RT-PCR. |
Reaction Conditions | 0, 1, 10, 100nM; 24h |
Applications | Parathyroid hormone (1-34) (human) induced an increase in Ang-1 mRNA expression. The Ang-1 mRNA levels, at 10nM Parathyroid hormone (1-34) (human), were 2-fold (207%±6.4) the levels of the control. Further increases in the concentration of Parathyroid hormone (1-34) (human) (to 100nM) did not further increase the levels of Ang-1 mRNA expression. |
| Animal experiment [2]: | |
Animal models | Female New Zealand white rabbits |
Preparation Method | Rabbits were randomized into six groups of 7 animals each as follows: 4-week vehicle administration group, 4-week Parathyroid hormone (1-34) (human) (TPTD) administration group (20μg/kg/day, s.c.), 12-week vehicle administration group, 4-week TPTD administration+8-week vehicle administration group, 4-week TPTD administration+8-week lower-dose ibandronate (IBN) administration group (20μg/kg, s.c., every 4 weeks), and 4-week TPTD administration+8-week higher-dose IBN administration group (100μg/kg, s.c., every 4 weeks). After the 4- or 12-week experimental period, the cortical bone of the distal femoral diaphysis was processed for HR-QCT analysis. |
Dosage form | 20μg/kg/day, for 4 weeks; s.c. |
Applications | Parathyroid hormone (1-34) (human) administration increased the pore ratio, number, and density as well as the cortical area, thickness, and bone mineral content (BMC), without significant influencing the volumetric bone mineral density (BMD). |
References: | |
| Cas No. | 52232-67-4 | SDF | |
| 别名 | 特立帕肽; Human parathyroid hormone-(1-34); hPTH (1-34) | ||
| 分子式 | C181H291N55O51S2 | 分子量 | 4117.75 |
| 溶解度 | ≥ 399.3mg/mL in DMSO, ≥ 19.88 mg/mL in Water | 储存条件 | -20°C, away from moisture and light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2429 mL | 1.2143 mL | 2.4285 mL |
| 5 mM | 0.0486 mL | 0.2429 mL | 0.4857 mL |
| 10 mM | 0.0243 mL | 0.1214 mL | 0.2429 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet